A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Neoplasms

Interventions

DRUG: IDRX-42
DRUG: Sunitinib

Sponsor

GlaxoSmithKline